600216 浙江医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)8.59911.4464.5495.98212.706
总资产报酬率 ROA (%)6.6828.7343.4084.3239.077
投入资产回报率 ROIC (%)7.86810.5234.1605.41111.300

边际利润分析
销售毛利率 (%)37.49442.33232.38734.47040.851
营业利润率 (%)15.65713.0464.8776.21812.920
息税前利润/营业总收入 (%)14.23512.8784.4375.58713.656
净利润/营业总收入 (%)12.94510.8823.5514.4689.689

收益指标分析
经营活动净收益/利润总额(%)101.043118.88330.963128.977103.750
价值变动净收益/利润总额(%)2.555-2.442-3.745-11.5008.109
营业外收支净额/利润总额(%)-0.190-0.893-4.646-2.692-2.246

偿债能力分析
流动比率 (X)2.7882.5632.2602.2941.995
速动比率 (X)2.0131.7331.4491.4851.376
资产负债率 (%)20.68921.22121.85621.90026.733
带息债务/全部投入资本 (%)7.3566.2657.4438.2849.517
股东权益/带息债务 (%)1,235.8711,470.2851,232.7411,100.412942.674
股东权益/负债合计 (%)378.014363.724344.798340.092262.045
利息保障倍数 (X)-10.219-243.513-19.773-11.94313.389

营运能力分析
应收账款周转天数 (天)62.63855.28558.89560.80951.636
存货周转天数 (天)132.685137.940136.804130.911111.783